RIMAG GROUP (02522) plans to discount approximately 12.53% of the 35 million shares allocated for sale, raising approximately HK$562 million.

RIMAG GROUP (02522) announced on August 22, 2025, that the company has entered into a placement agreement with the placing agent. According to this agreement, the placing agent has conditionally and individually agreed to act as the company's placing agent to use best efforts to facilitate at least six placing persons (including their ultimate beneficial owners who will be independent third parties) to purchase 35 million shares of placing shares at a placing price of HK$16.76 per share. Assuming that the number of shares issued from the date of this announcement to the completion date remains unchanged, the 35 million placing shares under the placement represent approximately 11.93% of the total number of H Shares issued as of the date of this announcement after the issuance and expansion of the placing shares (excluding treasury shares). The placing price per share is HK$16.76, representing a discount of approximately 12.53% from the closing price of H Shares on August 21, 2025 (last trading day) reported on the Stock Exchange. Assuming all placing shares are fully placed and completed, it is estimated that the net proceeds from the placement (after deduction of placement commission and related costs) will be approximately HK$562 million. The company intends to distribute the net proceeds from the placement as follows: Approximately 40% of the net proceeds from the placement will be used for the development of the data and artificial intelligence field, further deepening the data service capabilities such as medical imaging data mining, annotation, and cleaning, and researching and developing artificial intelligence application platforms to provide the full application scenarios of medical imaging processes. The company plans to establish deep strategic partnerships with leading enterprises in artificial intelligence and healthcare fields, as well as large-scale tertiary hospitals in China, to create data space, build convertible imaging centers, and establish equity investments in high-quality companies in this field; Approximately 30% of the net proceeds from the placement will be used to continue to expand the company's medical imaging center business and empower solution business through independent investments or acquisitions, in order to establish strategic strongholds in more domestic markets and radiate to overseas markets, such as China Hong Kong, Singapore, and other regions; Approximately 20% of the net proceeds from the placement will be used to participate in investments or establish industrial incubation funds to invest in high-quality medical industry companies that are synergistic with the group's business resources, to help the company establish more medical industry resources, establish industry influence, and build a closed-loop third-party medical service and ecosystem in China; and Approximately 10% of the net proceeds from the placement will be used for general working capital.